Effects of T cell immunoglobulin and mucin domain-containing molecule-3 signaling molecule on human monocyte-derived dendritic cells with hepatitis B virus surface antigen stimulation in vitro

Yu,Zhenjun; Jiang,Ting; Zhu,Min; Pan,Kechuan; Yan,Fei; Zhu,Jiansheng

doi:10.3892/mmr.2016.4815

Effects of T cell immunoglobulin and mucin domain-containing molecule-3 signaling molecule on human monocyte-derived dendritic cells with hepatitis B virus surface antigen stimulation in vitro

Authors:
- Zhenjun Yu
- Ting Jiang
- Min Zhu
- Kechuan Pan
- Fei Yan
- Jiansheng Zhu
View Affiliations

Affiliations: Medical Research Center of Taizhou Hospital, Wenzhou Medical University, Linhai, Zhejiang 317000, P.R. China, Department of Infectious Diseases, Affiliated Taizhou Hospital of Wenzhou Medical University, Linhai, Zhejiang 317000, P.R. China
Published online on: January 27, 2016 https://doi.org/10.3892/mmr.2016.4815
Pages: 2785-2790

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the in vitro effects of hepatitis B virus surface antigen (HBsAg) on the immune function of human monocyte-derived dendritic cells (MD‑DCs), and the moderating role of T cell immunoglobulin and mucin domain‑containing molecule‑3 (Tim‑3) signaling molecule. The monocytes, obtained from healthy adult peripheral blood, were incubated with recombinant human granulocyte‑macrophage colony‑stimulating factor and interleukin (IL)‑4 to induce DCs. DC‑associated cell markers were detected using flow cytometry. MD‑DCs were treated with HBsAg (5 µg/ml) in vitro for 48 h and subsequently, cell markers, lymphocyte stimulatory capacity, signaling protein and downstream cytokines were assessed. In addition, a Tim‑3 monoclonal antibody was used to inhibit the Tim‑3 signaling pathway, and subsequently the immune responses of MD‑DCs to HBsAg stimulation were determined using the aforementioned method. The cell phenotype expressions of MD‑DCs were all significantly increased with cluster of differentiation (CD)11c at 70.09±0.57%, human leukocyte antigen‑DR at 79.83±2.12%, CD80 at 48.33±7.34% and CD86 at 44.21±5.35%. The treatment of MD‑DCs with HBsAg resulted in a CD80 and CD86 enhanced expression, enhanced lymphocyte stimulatory capacity, upregulated expression of Tim‑3 and nuclear factor‑κB (NF‑κB), as well as enhanced cytokine secretion of IL‑6, IL‑10 and interferon (IFN)‑γ. However, a reduced immune response of MD‑DCs in response to HBsAg stimulation was observed when the Tim‑3 signaling pathway was inhibited prior to stimulation. The expression of NF‑κB was decreased and the cytokine secretion level of IL‑6, IL‑10 and IFN‑γ were downregulated. The treatment with HBsAg in vitro resulted in an enhanced immune response of MD‑DCs, which may be positively regulated by the Tim-3 signaling molecule.

View Figures

View References

1	Trépo C, Chan HL and Lok A: Hepatitis B virus infection. Lancet. 384:2053–2063. 2014. View Article : Google Scholar : PubMed/NCBI
2	Hatzakis A, Van Damme P, Alcorn K, Gore C, Benazzouz M, Berkane S, Buti M, Carballo M, Cortes Martins H, Deuffic-Burban S, et al: The state of hepatitis B and C in the Mediterranean and Balkan countries: Report from a summit conference. J Viral Hepat. 20(Suppl 2): 1–20. 2013. View Article : Google Scholar : PubMed/NCBI
3	Hösel M, Quasdorff M, Wiegmann K, Webb D, Zedler U, Broxtermann M, Tedjokusumo R, Esser K, Arzberger S, Kirschning CJ, et al: Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology. 50:1773–1782. 2009. View Article : Google Scholar : PubMed/NCBI
4	Mildner A and Jung S: Development and function of dendritic cell subsets. Immunity. 40:642–656. 2014. View Article : Google Scholar : PubMed/NCBI
5	Hänninen A: New dimensions for dendritic cells. Duodecim. 130:883–891. 2014.In Finnish.
6	Wang FS, Xing LH, Liu MX, Zhu CL, Liu HG, Wang HF and Lei ZY: Dysfunction of peripheral blood dendritic cells from patients with chronic hepatitis B virus infection. World J Gastroenterol. 7:537–541. 2001. View Article : Google Scholar
7	Hao HX, Zhang YL, Li MH, Zhang LX, Yi W, Hu YH, Yi N, Cheng J, Liu SA and Xie Y: Dendritic cell subsets and function in newborns from mothers of different HBV infection status. Zhong Hua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 27:112–114. 2013.In Chinese.
8	Ganem D and Prince AM: Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med. 350:1118–1129. 2004. View Article : Google Scholar : PubMed/NCBI
9	Chen Z, Cheng Y, Xu Y, Liao J, Zhang X, Hu Y, Zhang Q, Wang J, Zhang Z, Shen F and Yuan Z: Expression profiles and function of Toll-like receptors 2 and 4 in peripheral blood mononuclear cells of chronic hepatitis B patients. Clin Immunol. 128:400–408. 2008. View Article : Google Scholar : PubMed/NCBI
10	Wang S, Chen Z, Hu C, Qian F, Cheng Y, Wu M, Shi B, Chen J, Hu Y and Yuan Z: Hepatitis B virus surface antigen selectively inhibits TLR2 ligand-induced IL-12 production in monocytes/macrophages by interfering with JNK activation. J Immunol. 190:5142–5151. 2013. View Article : Google Scholar : PubMed/NCBI
11	Xu Y, Hu Y, Shi B, Zhang X, Wang J, Zhang Z, Shen F, Zhang Q, Sun S and Yuan Z: HBsAg inhibits TLR9-mediated activation and IFN-alpha production in plasmacytoid dendritic cells. Mol Immunol. 46:2640–2646. 2009. View Article : Google Scholar : PubMed/NCBI
12	Kondo Y, Ninomiya M, Kakazu E, Kimura O and Shimosegawa T: Hepatitis B surface antigen could contribute to the immunopatho-genesis of hepatitis B virus infection. ISRN Gastroenterol. 2013:9352952013. View Article : Google Scholar
13	Zhang XM and Shan NN: The role of T cell immunoglobulin and mucin domain-3 in immune thrombocytopenia. Scand J Immunol. 79:231–236. 2014. View Article : Google Scholar : PubMed/NCBI
14	Khademi M, Illés Z, Gielen AW, Marta M, Takazawa N, Baecher-Allan C, Brundin L, Hannerz J, Martin C, Harris RA, et al: T Cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis. J Immunol. 172:7169–7176. 2004. View Article : Google Scholar : PubMed/NCBI
15	Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX, Strom TB and Kuchroo VK: The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 6:1245–1252. 2005. View Article : Google Scholar : PubMed/NCBI
16	Jiang J, Jin MS, Kong F, Cao D, Ma HX, Jia Z, Wang YP, Suo J and Cao X: Decreased galectin-9 and increased Tim-3 expression are related to poor prognosis in gastric cancer. PLoS One. 8:e817992013. View Article : Google Scholar : PubMed/NCBI
17	Chapuis F, Rosenzwajg M, Yagello M, Ekman M, Biberfeld P and Gluckman JC: Differentiation of human dendritic cells from monocytes in vitro. Eur J Immunol. 27:431–441. 1997. View Article : Google Scholar : PubMed/NCBI
18	van der Molen RG, Sprengers D, Binda RS, de Jong EC, Niesters HG, Kusters JG, Kwekkeboom J and Janssen HL: Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology. 40:738–746. 2004. View Article : Google Scholar : PubMed/NCBI
19	Jan RH, Lin YL, Chen CJ, Lin TY, Hsu YC, Chen LK and Chiang BL: Hepatitis B virus surface antigen can activate human monocyte-derived dendritic cells by nuclear factor kappa B and p38 mitogen-activated protein kinase mediated signaling. Microbiol Immunol. 56:719–727. 2012. View Article : Google Scholar : PubMed/NCBI
20	Romani N, Reider D, Heuer M, Ebner S, Kämpgen E, Eibl B, Niederwieser D and Schuler G: Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods. 196:137–151. 1996. View Article : Google Scholar : PubMed/NCBI
21	Op den Brouw ML, Binda RS, van Roosmalen MH, Protzer U, Janssen HL, van der Molen RG and Woltman AM: Hepatitis B virus surface antigen impairs myeloid dendritic cell function: A possible immune escape mechanism of hepatitis B virus. Immunology. 126:280–289. 2009. View Article : Google Scholar :
22	Jan RH, Lin YL, Chen LK, Huang MT, Wang LC and Chiang BL: Hepatitis B virus surface antigen can activate dendritic cells and modulate T helper type immune response. Microbiol Immunol. 55:51–59. 2011. View Article : Google Scholar
23	Shen M, Wang S, Ge G, Xing Y, Ma X, Huang Z and Lu S: Profiles of B and T cell immune responses elicited by different forms of the hepatitis B virus surface antigen. Vaccine. 28:7288–7296. 2010. View Article : Google Scholar : PubMed/NCBI
24	Du X, Wang J, Kang Y, Xiao W, Zhao G and Wang B: Suppression of the antigen-specific T cell immune response by co-immunization with the HBV DNA vaccine and recombinant HBsAg. Wei Sheng Wu Xue Bao. 49:938–942. 2009.In Chinese. PubMed/NCBI
25	Tong HS, Zhang Y, Yuan K and Fu XW: HBsAg loading on dendritic cells in patients with chronic hepatitis B: Expressions of phenotypic molecules. Hepatobiliary Pancreat Dis Int. 5:56–59. 2006.PubMed/NCBI
26	Kang P, Luo SL and Li SC: Comparative study on dendritic cells stimulated with HBsAg or HBcAg in patients with chronic hepatitis B. Zhong Hua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 21:250–252. 2007.In Chinese.
27	Han G, Chen G, Shen B and Li Y: Tim-3: An activation marker and activation limiter of innate immune cells. Front Immunol. 4:4492013. View Article : Google Scholar : PubMed/NCBI
28	Anderson AC, Anderson DE, Bregoli L, Hastings WD, Kassam N, Lei C, Chandwaskar R, Karman J, Su EW, Hirashima M, et al: Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science. 318:1141–1143. 2007. View Article : Google Scholar : PubMed/NCBI
29	Kanzaki M, Wada J, Sugiyama K, Nakatsuka A, Teshigawara S, Murakami K, Inoue K, Terami T, Katayama A, Eguchi J, et al: Galectin-9 and T cell immunoglobulin mucin-3 pathway is a therapeutic target for type 1 diabetes. Endocrinology. 153:612–620. 2012. View Article : Google Scholar
30	Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H, Fujioka Y, Ohba Y, Gorman JV, Colgan JD, et al: Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol. 13:832–842. 2012. View Article : Google Scholar : PubMed/NCBI
31	Ju Y, Hou N, Meng J, Wang X, Zhang X, Zhao D, Liu Y, Zhu F, Zhang L, Sun W, et al: T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B. J Hepatol. 52:322–329. 2010. View Article : Google Scholar : PubMed/NCBI
32	Wu W, Shi Y, Li S, Zhang Y, Liu Y, Wu Y and Chen Z: Blockade of Tim-3 signaling restores the virus-specific CD8⁺ T-cell response in patients with chronic hepatitis B. Eur J Immunol. 42:1180–1191. 2012. View Article : Google Scholar : PubMed/NCBI